Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy
Levetiracetam is a relatively novel anti-epileptic drug (AED), which has proven to be
effective and well tolerated in many glioma patients with otherwise pharmacoresistant
epilepsy. Moreover, levetiracetam has neither enzyme-inducing nor enzyme-inhibiting
properties, which makes the drug particularly attractive for brain tumour patients, as they
frequently receive chemotherapy and/or corticosteroids. Therefore, levetiracetam is the
anti-epileptic drug of choice post-operatively in glioma patients suffering from epilepsy.
Unfortunately, even with levetiracetam, a proportion of glioma patients is not free of
seizures. It is unclear, however, which glioma patients benefit from levetiracetam
treatment. It is suggested that the expression of protein SV2A is correlated with clinical
response to levetiracetam. The determination of SV2A expression in brain (tumour) tissue
might be used as a predictive tool for response to levetiracetam.
Objective of this study: Correlation of SV2A expression in surgically removed tumour and
tumour-surrounding tissue of glioma patients suffering from epilepsy with their clinical
response to levetiracetam.
Observational Model: Cohort, Time Perspective: Prospective
to correlate the efficacy of post-operative levetiracetam monotherapy in newly diagnosed glioma patients suffering from epilepsy with expression of synaptic vesicle protein 2A (SV2A).
J.J. Heimans, prof. dr.
VU University Medical Center
Netherlands: Medical Ethics Review Committee (METC)